Jardiance Cost in Mississippi 2026: Cash Price, Medicaid, Compounding, and Insurance

What Is the Cash Price of Jardiance in Mississippi in 2026?

Without insurance or a discount program, Jardiance costs approximately $680 per month at Mississippi retail pharmacies in 2026. That figure reflects the Boehringer Ingelheim / Lilly wholesale acquisition cost and is consistent across CVS, Walgreens, Walmart, and Rite Aid locations throughout the state. GoodRx coupons can bring the price down to roughly $620 to $650 per month at select chains, depending on your zip code.

The $680 list price covers a 30-day supply of either the 10 mg or the 25 mg tablet. Both strengths carry the same price at retail. Because no FDA-approved generic empagliflozin exists as of 2026, there is no generic substitution option at the pharmacy counter.

Mississippi ranks among the states with the highest rates of type 2 diabetes in the country. The Centers for Disease Control and Prevention reported a state diabetes prevalence of 15.8% in its most recent National Diabetes Statistics Report [1], meaning a large share of residents face this pricing reality every month. The full cost burden is significant, particularly because Mississippi also has one of the lower median household incomes in the United States.

Patients who pay cash should call at least three pharmacies before filling, because pharmacy-level negotiated rates vary even within the same city. Walmart's $4 / $10 generic program does not include Jardiance, and no branded SGLT2 inhibitor sits on that list.

Does Mississippi Medicaid Cover Jardiance?

Mississippi Medicaid does not cover Jardiance as of 2026. The drug is not on the Mississippi Division of Medicaid preferred drug list for any of its three currently approved indications: type 2 diabetes, heart failure with reduced or preserved ejection fraction, or chronic kidney disease.

This is a meaningful gap. The American Diabetes Association's 2024 Standards of Care in Diabetes explicitly recommends SGLT2 inhibitors for patients with type 2 diabetes who also have established cardiovascular disease, heart failure, or diabetic kidney disease, stating that these agents should be used "independent of HbA1c" in those populations [2]. Mississippi's Medicaid non-coverage effectively puts that guideline recommendation out of reach for the state's low-income population without a prior authorization pathway or a successful appeal.

Patients on Mississippi Medicaid who need empagliflozin have two realistic paths. First, a prescribing physician can submit a prior authorization request citing clinical necessity, particularly if the patient has a documented diagnosis of heart failure or CKD, where the mortality data from EMPA-REG OUTCOME and EMPEROR-Reduced are hardest to argue with [3]. Second, a licensed 503A compounding pharmacy can dispense compounded empagliflozin outside the Medicaid formulary, though Medicaid will not reimburse that either.

Dual-eligible patients (Medicare and Medicaid) face a different set of rules. Medicare Part D plans in Mississippi vary in their Jardiance coverage, and some do place it on formulary at tier 2 or tier 3 with cost-sharing. Checking the Medicare Plan Finder at CMS.gov with a specific NDC number is the most reliable way to verify your plan's coverage for 2026.

Which Insurance Plans Cover Jardiance in Mississippi?

Most commercial insurance plans in Mississippi cover Jardiance, but the tier placement and required cost-sharing differ considerably. Blue Cross Blue Shield of Mississippi, United Healthcare, Aetna, Cigna, and Humana all list empagliflozin on their formularies for at least one indication, typically at tier 3 (preferred brand) or tier 4 (non-preferred brand).

Tier 3 cost-sharing on a typical Mississippi employer-sponsored plan runs between $45 and $100 per month after deductible. Tier 4 cost-sharing can reach $150 to $250 per month. Many plans require prior authorization for the heart failure or CKD indications, even when they cover the drug freely for type 2 diabetes.

The ACA Marketplace plans available through HealthCare.gov in Mississippi for plan year 2026 include Silver and Gold tier options that cover Jardiance. Bronze plans are less consistent. Because deductibles on Bronze plans often exceed $7,000, a patient who hits no other medical costs may pay the full $680 list price for several months before cost-sharing kicks in.

One practical action: ask your prescribing clinician to submit a letter of medical necessity when filing a prior authorization for a cardiovascular or renal indication. In the EMPEROR-Reduced trial (N=3,730), empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% compared with placebo (hazard ratio 0.75; 95% CI 0.65 to 0.86; P<0.001) [3]. That trial result is the kind of evidence that overturns prior authorization denials on appeal.

How Does the Boehringer Ingelheim / Lilly Savings Card Work in Mississippi?

The Jardiance savings card, administered jointly by Boehringer Ingelheim and Eli Lilly, lets eligible commercially insured patients pay as little as $10 per month for a 30-day or 90-day supply. Mississippi residents can enroll online at jardiance.com or through a participating pharmacy at the point of sale.

The program has specific exclusions. Patients whose primary coverage is a federal or state government program, including Medicare, Medicaid, TRICARE, or the VA, are not eligible. Mississippi Medicaid patients cannot use the card. Medicare Part D patients cannot use it either, because federal anti-kickback rules prohibit manufacturer coupons from applying to Part D costs.

For eligible patients, the card typically covers the gap between the plan's cost-sharing and a $10 out-of-pocket maximum, up to a maximum annual benefit of approximately $5,400. The card is reloadable each January. Enrollment is free and requires no income verification.

Patients who lose commercial insurance coverage mid-year, for example after a job change, should re-evaluate their eligibility immediately. A lapse in commercial coverage makes the card inapplicable, and the full cash price would apply unless another savings program is in place.

Is Compounded Empagliflozin Legal in Mississippi?

Compounded empagliflozin is legal in Mississippi when prepared by a state-licensed 503A compounding pharmacy operating under a valid prescription. Mississippi's Board of Pharmacy recognizes 503A compounding pharmacies, which operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and are regulated by state boards rather than directly by the FDA in most circumstances.

The legal picture has nuance. The FDA designated semaglutide (a different GLP-1 drug) as in shortage, which opened a specific compounding window. Empagliflozin has not been on the FDA drug shortage list, which means the pathway for 503B outsourcing facilities to compound it in bulk is narrower. A 503A pharmacy, however, can compound empagliflozin for an individual patient under a valid prescription without relying on a shortage designation, provided the compounded version is not essentially a copy of the commercially available product and meets the standard of being tailored to the individual patient's clinical needs [4].

The clinical case for compounding typically rests on one of three scenarios. A patient may have a documented allergy or sensitivity to an inactive ingredient in the commercial tablet. A prescriber may need a dose or delivery form not commercially available. Or cost is the primary barrier and the prescriber documents that the commercially available product is inaccessible to the patient. Mississippi clinicians considering this route should consult the Mississippi Board of Pharmacy's guidance and confirm the compounding pharmacy's state licensure before writing the prescription.

Cost for compounded empagliflozin varies by pharmacy. Some 503A pharmacies serving Mississippi patients charge considerably less than the $680 list price for commercial Jardiance, with prices ranging from roughly $40 to $180 per month depending on dose, quantity, and formulation. These prices are not standardized and can change without notice.

Quality is not guaranteed in the same way as FDA-approved manufacturing. Patients and prescribers should ask for a certificate of analysis confirming potency, purity, and sterility (if applicable) for every batch.

Why Does Jardiance Cost So Much Without Insurance?

Jardiance's price reflects Boehringer Ingelheim and Lilly's market exclusivity on the empagliflozin molecule. The drug received its initial FDA approval for type 2 diabetes in 2014, with subsequent approvals for heart failure with reduced ejection fraction (2021), heart failure with preserved ejection fraction (2022), and chronic kidney disease (2023) [5]. Each additional indication extended the commercial value of the franchise without resetting the patent clock in a simple way, and no generic filer has yet received FDA approval.

The EMPA-REG OUTCOME trial (N=7,020), published in the New England Journal of Medicine in 2015, demonstrated that empagliflozin reduced the risk of cardiovascular death by 38% (hazard ratio 0.62; 95% CI 0.49 to 0.77; P<0.001) compared with placebo in patients with type 2 diabetes and established cardiovascular disease [6]. That mortality signal is unusually strong for an oral diabetes drug and contributed to the drug's rapid formulary adoption and sustained pricing power.

Patent expiration timelines suggest that generic empagliflozin could enter the U.S. market as early as 2025 or 2026 for some formulations, though litigation between Boehringer Ingelheim and generic manufacturers has delayed FDA tentative approvals in some cases. Patients should check the FDA's Orange Book (updated monthly) for the current status of any authorized generics or first-to-file applicants [5].

What Are All the Ways to Reduce Jardiance Cost in Mississippi?

Patients in Mississippi have several concrete options beyond paying the $680 list price.

The manufacturer savings card is the single largest discount available to commercially insured patients, dropping the monthly cost to $10 for those who qualify. Enrollment takes about five minutes online.

GoodRx, RxSaver, and NeedyMeds all offer Jardiance coupons that bring the price to the $620 to $650 range at major chains. These are better than paying list price but still represent a substantial monthly expense. Costco and Sam's Club pharmacies sometimes have slightly lower pharmacy-negotiated prices and are open to non-members in some states, though Mississippi Costco pharmacies may require membership.

The Boehringer Ingelheim Cares Foundation offers a patient assistance program for uninsured or underinsured patients who meet income criteria. Patients with household incomes at or below 400% of the federal poverty level may qualify for free medication directly from the manufacturer. Applications are available at boehringer-ingelheim.us or through the prescribing clinic.

NeedyMeds.org maintains a searchable database of state-specific assistance programs and has a specific listing for Mississippi residents seeking diabetes medication support.

For patients who do not qualify for any of the above, a telehealth-based prescriber can evaluate whether compounded empagliflozin is clinically appropriate and legally supportable given the patient's specific circumstances. That conversation takes roughly 20 to 30 minutes and can happen from a Mississippi patient's home.

Can I Get Jardiance Through Telehealth in Mississippi?

Telehealth prescribing of Jardiance is legal in Mississippi. State law permits synchronous audio-video consultations to establish a patient-provider relationship, after which a licensed Mississippi prescriber can write a prescription for empagliflozin and send it to any in-state or mail-order pharmacy.

Mississippi's telehealth parity law requires most insurance plans to reimburse telehealth visits at the same rate as in-person visits for equivalent services. That means an established patient managing type 2 diabetes who sees a HealthRX or other telehealth provider via video can have the visit billed to insurance in the same way an office visit would be.

Telehealth is particularly relevant for Mississippi patients in rural counties where endocrinologists and cardiologists are scarce. Mississippi has fewer than 25 board-certified endocrinologists, and many are concentrated in Jackson. A primary care telehealth visit can initiate or continue empagliflozin therapy for appropriate patients without a 90-minute drive.

The prescriber still needs to document the appropriate indication (type 2 diabetes, heart failure, or CKD), confirm contraindications such as eGFR <20 mL/min/1.73 m2 or a history of recurrent diabetic ketoacidosis, and set up appropriate lab monitoring, typically a basic metabolic panel and urinalysis at baseline and at least annually [2].

What Clinical Evidence Supports Using Jardiance?

Empagliflozin has one of the strongest cardiovascular outcomes datasets of any diabetes drug. EMPA-REG OUTCOME (N=7,020) showed a 38% relative reduction in cardiovascular mortality at a median follow-up of 3.1 years in patients with type 2 diabetes and established cardiovascular disease, with an absolute risk reduction of 2.6 percentage points [6]. That result changed practice guidelines worldwide.

EMPEROR-Reduced (N=3,730) extended the evidence to patients with heart failure with reduced ejection fraction regardless of diabetes status, showing a 25% reduction in the composite of cardiovascular death or heart failure hospitalization [3]. EMPEROR-Preserved (N=5,988) then demonstrated a 21% reduction in the same composite in patients with heart failure with preserved ejection fraction, a condition for which effective therapies had been historically limited [7].

The EMPA-KIDNEY trial (N=6,609) showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% compared with placebo in patients with CKD, including those without diabetes, with an eGFR as low as 20 mL/min/1.73 m2 [8].

As the American College of Cardiology's 2022 heart failure guideline states, SGLT2 inhibitors are recommended "to reduce hospitalizations for HF and cardiovascular mortality" and carry a Class I recommendation for HFrEF [9]. That is the highest recommendation class in ACC/AHA nomenclature.

Monitoring Requirements and Safety Considerations in Mississippi Practice

Starting empagliflozin requires a baseline eGFR measurement. The drug offers less glycemic benefit and should generally not be initiated when eGFR is <30 mL/min/1.73 m2 for the diabetes indication, though it can be continued for cardiorenal protection at lower eGFR values per the updated labeling.

Key safety points for Mississippi prescribers and patients include the following. Genital mycotic infections (yeast infections) occur in roughly 6% to 9% of women and 3% to 4% of men taking SGLT2 inhibitors, more often in patients with prior infections or poor hygiene [5]. Fournier's gangrene (necrotizing fasciitis of the genitalia) is rare but has been reported; patients should be counseled to seek immediate care for pain, tenderness, or erythema in the genital or perineal area.

Euglycemic diabetic ketoacidosis is possible, particularly in patients who are fasted, dehydrated, or undergoing surgery. The standard clinical guidance is to hold empagliflozin at least 3 days before elective surgery and resume only after the patient is eating and drinking normally [2].

Blood pressure may drop modestly, particularly in the first weeks. Patients on loop diuretics or with baseline systolic pressure <100 mmHg should be monitored more closely at initiation.